Board meeting on Nov 3, 2026 to approve Q2 and H1 FY26-27 results

Results View source PDF Explain this filing

MEDANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹1194.60

prior close

₹1192.00

announcement price

After-mkt

timing

Nifty Midcap 150market-2.1%+0.9% vs market

Hospital peers, median of 26sector-0.8%-0.4% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Midcap 150 and 0.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

-0.3

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-2.1+0.9-0.8-0.4

Next day

+1.3-1.0+2.4+0.2+1.2

+5.5pendingpending+1.4+4.1

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Global Health Limited (Medanta) has informed BSE that its Board of Directors will meet on Tuesday, November 3, 2026 to consider and approve the Unaudited Financial Results for the second quarter and half year ended September 30, 2026. The trading window is already closed from October 1, 2026 and will reopen 48 hours after results are declared.

Likely market impact

Routine board meeting intimation. Investors should watch for the Q2 and H1 results announcement post November 3, 2026.